Natriumklorid Fresenius Kabi (Sodium Chloride)

Sodium chloride, the active ingredient in Natriumklorid Fresenius Kabi, is an electrolyte presented as an injection solution for intravenous use. It is employed to replace lost fluids and electrolytes, correct hyponatremia, and restore intravascular volume in patients with hypovolemia.

GNH USA supplies Natriumklorid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Natriumklorid Fresenius Kabi is an intravenous electrolyte solution used in several clinical situations involving fluid balance and sodium deficits. - Fluid and electrolyte replacement: restores extracellular sodium and chloride and expands intravascular volume. - Hypovolemia: increases circulating blood volume to improve tissue perfusion. - Hyponatremia: raises serum sodium concentration toward normal levels.

Adverse reactions may occur with any intravenous therapy. Most are mild and reversible.

Common Side Effects: - Injection site pain or erythema - Mild fever or chills - Transient hypernatremia - Peripheral edema - Phlebitis - Electrolyte imbalance (mild)

Serious or Rare Side Effects: - Volume overload leading to pulmonary edema - Severe hypernatremia with neurologic signs - Anaphylactic or severe allergic reaction - Cardiac arrhythmia due to electrolyte shifts - Severe hypertension - Acute renal failure in predisposed patients

Before administering Natriumklorid Fresenius Kabi, clinicians should consider several safety measures. - Assess fluid status: evaluate volume status and ongoing losses. - Monitor serum electrolytes: check sodium and chloride levels regularly. - Adjust infusion rate in cardiac or renal disease: avoid rapid volume expansion. - Use caution in neonates and infants: dose and rate must be carefully controlled. - Avoid rapid large‑volume infusion unless clinically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium chloride may interact with other agents that affect fluid and electrolyte balance.

Major Interactions (Avoid): - Concomitant hypertonic saline solutions: risk of severe hypernatremia. - Large‑volume blood product transfusions without electrolyte monitoring. - Potassium‑sparing diuretics when combined with high‑volume saline may cause electrolyte disturbances.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate changes in renal perfusion. - Loop diuretics: increased sodium loss may require adjustment of saline volume. - Corticosteroids: can affect sodium retention and fluid balance. - Anticoagulants: rapid volume expansion may influence hemodynamics and bleeding risk.